What is Viibryd (vilazodone) and what does it do in the brain?
Viibryd (vilazodone) is an antidepressant. Its mechanism of action combines two major effects on serotonin signaling plus modulation of serotonin receptors. Specifically, vilazodone acts as a serotonin reuptake inhibitor and also directly interacts with serotonin (5-HT) receptors, including acting as a 5-HT1A receptor partial agonist.
How does Viibryd’s serotonin reuptake inhibition work?
Vilazodone inhibits the serotonin transporter (SERT), which reduces serotonin reuptake back into neurons. That raises serotonin signaling in synapses, a strategy similar in intent to other serotonin reuptake–based antidepressants (though vilazodone also has the additional receptor activity noted above).
What does “5-HT1A partial agonist” mean for Viibryd?
Vilazodone is a partial agonist at the 5-HT1A receptor. Partial agonism means it can activate the receptor, but only to an extent that depends on the existing serotonin environment. This receptor-level activity is part of why vilazodone is often described as having both SSRI-like and serotonergic-receptor–modulating properties.
How is Viibryd different from an SSRI like sertraline or fluoxetine?
Unlike classic SSRIs that mainly focus on blocking serotonin reuptake, vilazodone also has direct receptor effects (notably 5-HT1A partial agonism). That combination is the central mechanistic difference people usually look for when comparing vilazodone to more purely SERT-targeting antidepressants.
Why do these mechanisms matter clinically?
By increasing synaptic serotonin (via SERT inhibition) and simultaneously modulating 5-HT1A receptor activity, vilazodone may influence both mood-related circuits and serotonin feedback pathways involved in anxiety and other depression symptoms.
Sources
- DrugPatentWatch.com – Viibryd (vilazodone)